Failure of HIV-1 protease inhibitors to fully suppress viral replication: Implications for salvage therapy

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 175-182

  Deeks, S G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ABDOMINAL DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CROSS RESISTANCE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALAISE; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033281851     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_17     Document Type: Conference Paper

References (23)

1. HIV-1 protease inhibitors: A review for clinicians
2. 3
3. 3
4. Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic
5. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
6. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA Panel
7. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
8. Soft gel capsule saquinavir (sgcSQV) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients
9. A preliminary study of ritonavir, and inhibitor of HIV-1 protease, to treat HIV-1 infection
10. Indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): Concurrent or sequential therapy in ZDV-experienced patients
11. Combination use of ritonavir and saquinavir in HIV-infected patients: Preliminary safety and activity data
12. Combination use of ritonavir and saquinavir in HIV-infected patients: Preliminary safety and activity data
13. In vivo resistance to a human immunodeficiency virus type 1 protease inhibitor: Mutations, kinetics, and frequencies
14. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
15. Ordered accumulation of mutations to an HIV-1 protease confers resistance to ritonavir
16. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other HIV-1 protease inhibitors
17. ACTG 333: Antiviral effects of switching from saquinavir hard capsule (SQVhc) to saquinavir soft gelatin capsule (SQVsgc) vs. switching to indinavir (IDV) after prior saquinavir
18. Selection of saquinavir-resistant mutants following a switch from saquinavir
19. Virologic effect on ritonavir (RTV) plus saquinavir (SQV) in subjects who have failed indinavir (IDV)
20. Ritonavir/saquinavir (RTV/SQV) as Salvage Therapy after Failure of Initial Protease Inhibitor (PI) Regimen
21. Pilot study of nelfinavir, saquinavir-soft gel capsule, abacavir with and without nevirapine in patients who have failed an indinavir-containing regimen
22. Experience with ritonavir/saquinavir based regimen for the treatment of HIV-infection in subjects developing increased viral loads while receiving nelfinavir